Effect of intravitreal injection of dexamethasone implant on corneal endothelium in macular edema due to retinal vein occlusion

References

• London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011;28:351–366
   PubMed Web of Science ®Google Scholar
• Grosser T, Smyth EM, FitzGerald GA. Anti-inflammatory, antipyritic, and analgesic agents; pharmacology of gout. In: Brunton L, Chabner B, Knollmann B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. New York: McGraw-Hill Professional; 2010:959–1004
   Google Scholar
• Quaroni A, Tian JQ, Göke M, Podolsky DK. Glucocorticoids have pleiotropic effects on small intestinal crypt cells. Am J Physiol 1999;277:G1027–G1040
   PubMed Web of Science ®Google Scholar
• Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259–266
   PubMed Web of Science ®Google Scholar
• Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology 1991;98:1370–1375
   PubMed Web of Science ®Google Scholar
• Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006;203:1883–1889
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006;27:413–426
   PubMed Web of Science ®Google Scholar
• Saklatvala J. Glucocorticoids: do we know how they work? Arthritis Res 2002;4:146–150
   PubMedGoogle Scholar
• Wilson SE, Lloyd SA, He YG. Glucocorticoid receptor and interleukin-1 receptor messenger RNA expression in corneal cells. Cornea 1994;13:4–8
   PubMed Web of Science ®Google Scholar
• Stokes J, Noble J, Brett L, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000;41:1629–1638
   PubMed Web of Science ®Google Scholar
• McCarey BE, Edelhauser HF, Lynn MJ. Review of corneal endothelial specular microscopy for FDA clinical trials of refractive procedures, surgical devices, and new intraocular drugs and solutions. Cornea 2008;27:1–16
   PubMed Web of Science ®Google Scholar
• Parodi MB, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophthalmologica 2009;223:298–305
   PubMed Web of Science ®Google Scholar
• Glanville J, Patterson J, McCool R, Ferreira A, Gairy K, Pearce I. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol 2014;14:7
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80–86
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al.; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309–317
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146.e3
   PubMed Web of Science ®Google Scholar
• Schmitz K, Maier M, Clemens CR, et al.; German Retinal Vein Occlusion Group. [Reliability and safety of intravitreal Ozurdex injections: the ZERO study]. Ophthalmologe 2014;111:44–52
   PubMed Web of Science ®Google Scholar
• Pichi F, Specchia C, Vitale L, et al. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. Am J Ophthalmol 2014;157:607–615.e1
   PubMed Web of Science ®Google Scholar
• Tai LY, Khaw KW, Ng CM, Subrayan V. Central corneal thickness measurements with different imaging devices and ultrasound pachymetry. Cornea 2013;32:766–771
   PubMed Web of Science ®Google Scholar
• Chen WL, Lin CT, Yao CC, et al. In-vitro effects of dexamethasone on cellular proliferation, apoptosis, and Na+-K+-ATPase activity of bovine corneal endothelial cells. Ocul Immunol Inflamm 2006;14:215–223
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Zhang C, et al. Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J Nanomed 2009;4:175–183
   PubMed Web of Science ®Google Scholar
• Jamil AZ, Ahmed A, Mirza KA. Effect of intracameral use of dexamethasone on corneal endothelial cells. J Coll Physicians Surg Pak 2014;24:245–248
   PubMed Web of Science ®Google Scholar
• Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty: a pilot study. Transpl Int 2002;15:81–88
   PubMed Web of Science ®Google Scholar
• Dixit NV, Shah SK, Vasavada V, et al. Outcomes of cataract surgery and intraocular lens implantation with and without intracameral triamcinolone in pediatric eyes. J Cataract Refract Surg 2010;36:1494–1498
   PubMed Web of Science ®Google Scholar
• Ventura MC, Ventura BV, Ventura CV, et al. Congenital cataract surgery with intracameral triamcinolone: pre- and postoperative central corneal thickness and intraocular pressure. J AAPOS 2012;16:441–444
   PubMed Web of Science ®Google Scholar
• Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014;121:67–71
   PubMed Web of Science ®Google Scholar
• Tan DT, Chee SP, Lim L, Lim AS. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 1999;106:223–231
   PubMed Web of Science ®Google Scholar
• Wadood AC, Armbrecht AM, Aspinall PA, Dhillon B. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. J Cataract Refract Sur 2004;30:761–768
   PubMed Web of Science ®Google Scholar
• Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, et al. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 2010;29:849–852
   PubMed Web of Science ®Google Scholar
• Chiang CC, Chen WL, Lin JM, Tsai YY. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol 2008;146:688–691
   PubMed Web of Science ®Google Scholar